Alimi Y S, Hakam Z, Hartung O, Boufi M, Barthèlemy P, Aissi K, Dubuc M
Department of Vascular Surgery, University Hospital Nord, Marseille, France.
Eur J Vasc Endovasc Surg. 2008 Mar;35(3):346-52. doi: 10.1016/j.ejvs.2007.09.005. Epub 2007 Nov 5.
To evaluate superficial femoral artery (SFA) occlusive disease treatment by means of covered stents.
retrospective.
From 2000 to 2005, a Hemobahn/Viabahn endoprosthesis was implanted in 102 limbs (95 patients; mean age: 72.1 years, 52-94) for intermittent claudication (group I, n=50 limbs), critical (group II, n=32) or acute ischemia (group III, n=20). Lesions treated were Trans-Atlantic Inter-Society Consensus (TASC) A (n=9) B (n=42), C (n=28) or D (n=23), associated with a good (2 or 3 leg arteries, n=60) or a poor (1 or 0 artery, n=42) runoff.
The endograft was placed successfully in all cases, but 3 early deaths (3.2%) (1 in group II and 2 in group III), and 4 acute thromboses (4%) occurred. Primary and secondary actuarial patency rates were 97+/-1.7%, and 99+/-1% at 1 month, 74+/-4.8% & 84+/-4.1% at 1 year,and 71+/-9.5% & 79+/-8.5% at 3 years, after a mean follow-up of 30.2 months (1-60). Long-term primary and secondary patencies were significantly different between TASC Cand TASC D lesions (P<.004 & .001).
Severity of lesions, rather than preoperative symptoms or runoff, is mainly to be considered before using Hemobahn/Viabahn endoprosthesis in severe SFA occlusive lesions.
评估带膜支架治疗股浅动脉（SFA）闭塞性疾病的效果。
回顾性研究。
2000年至2005年期间，对102条肢体（95例患者；平均年龄：72.1岁，52 - 94岁）植入Hemobahn/Viabahn血管内支架，用于治疗间歇性跛行（I组，n = 50条肢体）、严重肢体缺血（II组，n = 32条）或急性肢体缺血（III组，n = 20条）。治疗的病变包括跨大西洋协作组（TASC）分级A（n = 9）、B（n = 42）、C（n = 28）或D（n = 23），同时伴有良好（2或3条下肢动脉，n = 60）或较差（1条或0条动脉，n = 42）的侧支循环。
所有病例均成功植入血管内支架，但发生了3例早期死亡（3.2%）（II组1例，III组2例），以及4例急性血栓形成（4%）。术后1个月时的初次和二次预期通畅率分别为97±1.7%和99±1%，1年时分别为74±4.8%和84±4.1%，3年时分别为71±9.5%和79±8.5%，平均随访30.2个月（1 - 60个月）。TASC C级和TASC D级病变的长期初次和二次通畅率存在显著差异（P <.004和.001）。
在严重的股浅动脉闭塞性病变中使用Hemobahn/Viabahn血管内支架之前，主要应考虑病变的严重程度，而非术前症状或侧支循环情况。
